GlassScriptPhysician profile
Michael S Wong
NPI 1346226834
$11,537.31
in general payments reported to CMS, 2019-2025
43 companies · $2,036 in 2025
The $2,036 reported for 2025 was more than what 94% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,863 · 2020: $1,081 · 2021: $1,099 · 2022: $1,173 · 2023: $1,973 · 2024: $2,312 · 2025: $2,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,321.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,651.93 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Merck Sharp & Dohme LLC | $1,209.07 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $956.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $869.43 | 2022-2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $659.03 | 2022-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $585.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $453.66 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Mdd US Operations, LLC | $356.92 | 2019-2020 | |
| Eisai INC. | $349.27 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $322.31 | 2022 | |
| Arbor Pharmaceuticals, INC. | $315.77 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $300.57 | 2019-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $299.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $291.98 | 2019-2024 | Trintellix |
| Scilex Pharmaceuticals INC. | $234.87 | 2021-2024 | Ztlido |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.